# US 2020/0399611 A1 · Microenvironments for self-assembly of islet organoids from stem cells differentiation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399611 A1
- Document ID: US20200399611A1
- Status: Published application
- Kind: A1
- Application number: 17/013,830
- Filed: 2020-09-07
- Published: 2020-12-24
- Earliest claimed: 2017-03-30
- Assignees: The Research Foundation for The State University of New York
- Applicants: The Research Foundation for The State University of New York
- Inventors: Sha Jin; Kaiming Ye; Huanjing Bi
- Web page: https://patentgrep.com/patent/US20200399611A1

## CPC

- C12N 5/0677: {Three-dimensional culture, tissue culture or organ culture; Encapsulated cells}
- A61L 27/14: Macromolecular materials
- A61L 27/3633: {Extracellular matrix [ECM]}
- A61L 27/3695: {characterised by the function or physical properties of the final product, where no specific conditions are defined to achieve this (A61L27/3687, A61L27/3691 take precedence)}
- C12N 5/0647: {Haematopoietic stem cells; Uncommitted or multipotent progenitors}
- C12N 5/0696: {Artificially induced pluripotent stem cells, e.g. iPS}
- A61L 2430/34: for soft tissue reconstruction
- C12N 2501/117: Keratinocyte growth factors (KGF-1, i.e. FGF-7; KGF-2, i.e. FGF-12)
- C12N 2501/16: Activin; Inhibin; Mullerian inhibiting substance
- C12N 2501/599: with CD designations not provided for elsewhere
- C12N 2533/54: Collagen; Gelatin
- C12N 2533/90: Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

Human pluripotent stem cells (hPSCs) are promising cell source to produce therapeutic endocrine cells for diabetes treatment. A gel solution made by decellularized tissue-specific extracellular matrix (dpECM) significantly promotes three-dimensional (3D) islet-like organogenesis during induced hPSC differentiation into endocrine lineages. Islet organoids are self-organized even in a two-dimensional (2D) culture mode. Cells derived from hPSCs differentiated on such ECM coated substrates exhibit similar cellular composition to native pancreatic islets. These cells express islet signature markers insulin, PDX-1, C-peptide, MafA, glucagon, somatostatin, and pancreatic polypeptide, and secrete more insulin in response to glucose level compared to a traditional matrix substrate (Matrigel). The dpECM facilitates generating more C-peptide+/glucagon− cells rather than C-peptide+/glucagon+ cells. Remarkably, dpECM also facilitated intra-organoid vascularity by generating endothelial cells and pericytes. Furthermore, dpECM niches also induced intra-organoid microvascularization during pancreatic differentiation.

## Claims

### Claim 1

A method of creating a synthetic organoid, comprising:
extracting tissue-specific matrix from a mammalian organ;
coating a growth surface with cell growth factors comprising collagen and mucopolysaccharides, and the extracted tissue-specific matrix;
culturing stem cells on the surface; and
inducing the stem cells to differentiate on the surface.

### Claim 2 (depends on 1)

The method according to claim 1, wherein said inducing the stem cells to differentiate on the surface further comprises differentiating the step cells to produce at least four coexisting distinct cell types which are differentiated with respect to the stem cells.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the cell growth factors comprise a solubilized basement membrane preparation extracted from a cell culture, comprising laminin, collagen IV, heparin sulfate proteoglycans, and entactin/nidogen.

### Claim 4 (depends on 1)

The method according to claim 1, further comprising cross linking the collagen after commencing culturing of the stem cells on the surface.

### Claim 5 (depends on 1)

The method according to claim 1, wherein:
the tissue-specific matrix comprises pancreas tissue-specific matrix from a mammal; and
the stem cells are pluripotent stem cells;
wherein said inducing the stem cells to differentiate on the surface comprises inducing the pluripotent stem cells to differentiate through at least four stages of differentiation on the surface into differentiated pancreatic cells.

### Claim 6 (depends on 5)

The method according to claim 5, wherein the pluripotent stem cells differentiate into at least pancreatic beta cells; pancreatic alpha cells; pancreatic delta cells; and pancreatic polypeptide cells, and the differentiated pluripotent stem cells comprise:
about 50-70% pancreatic beta cells;
about 20-30% pancreatic alpha cells;
about 10% pancreatic delta cells; and
about <5% pancreatic polypeptide cells.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the mammalian organ is a pancreas, the stems cells are human pluripotent stem cells, and said inducing comprises inducing the stem cells to differentiate through at least four stages of differentiation, further comprising producing human insulin and human somatostatin from the synthetic organoid.

### Claim 8 (depends on 7)

The method according to claim 7, further comprising testing the synthetic organoid for a modulation of a response to glucose selectively dependent on at least one drug.

### Claim 9 (depends on 1)

The method according to claim 1, wherein said inducing the stem cells to differentiate comprises sequentially incubating the stem cells in:
Media in Stage 1 (S1): RPMI 1640 containing B27, 50 ng/ml activin A and 0.5-1 mM sodium butyrate;
Media in Stage 2 (S2): RPMI 1640 containing B27, 250 μM ascorbic acid, 50 ng/ml keratinocyte growth factor, 50 ng/ml Noggin, 1 μM retinoic acid, 300 nM (−)-indolactam V, and 100 nM LDN193189;
Media in Stage 3 (S3): DME/F12 containing B27, 1 μM RA, 200 nM LDN, 300 nM ILV, 1 μM 3,3′,5-Triiodo-L-thyronine sodium salt, 10 μM ALK5 inhibitor II, and 10 μg/ml heparin, supplemented with glucose to a final concentration of 20 mM;
Media in Stage 4 (S4): RPMI 1640 containing B27, 1 μM T3, 10 μM ALKi, 1 mM N-acetyl cysteine, 0.5 μM R428, 10 μM trolox, 100 nM γ-secretase inhibitor XX, 10 μM zinc sulfate, 10 mM nicotinamide, and 10 μg/ml HP, supplemented with glucose to a final concentration of 20 mM glucose; and
Media in Stage 5 (S5): CMRL supplement containing 10% fetal bovine serum, 1 μM T3, 10 μM ALKi, 0.5 μM R428, and 10 mM Nic.

### Claim 10 (depends on 9)

The method according to claim 9, wherein the synthetic organoid comprises pancreatic alpha cells, pancreatic beta cells, pancreatic delta cells, and pancreatic polypeptide cells, further comprising implanting the synthetic organoid into a mammal.

### Claim 11 (depends on 1)

The method according to claim 1, wherein the synthetic organoid is maintained within an extracorporeal blood circulation loop of a mammal.

### Claim 12

A synthetic pancreatic islet organoid, comprising:
a pancreas tissue-specific matrix;
a collagen support material;
about 50-70% pancreatic beta cells;
about 20-30% pancreatic alpha cells;
about 10% pancreatic delta cells; and
about <5% pancreatic polypeptide cells,
the pancreatic beta cells, pancreatic alpha cells, pancreatic delta cells, and pancreatic polypeptide cells being derived from mammalian pluripotent stem cells, and
the pancreas tissue-specific matrix being derived from a mammal.

### Claim 13 (depends on 12)

The synthetic pancreatic islet organoid according to claim 12, wherein the pancreas tissue specific matrix is processed for cellular removal, substantially without detergent treatment.

### Claim 14 (depends on 13)

The synthetic pancreatic islet organoid according to claim 13, wherein the pancreas tissue-specific matrix is processed for cellular removal by cycles of high and low osmotic tension.

### Claim 15 (depends on 12)

The synthetic pancreatic islet organoid according to claim 12, wherein the pancreas tissue-specific matrix has a residual DNA content of less than about 1% of the DNA of the mammalian tissue from which it is derived.

### Claim 16 (depends on 12)

The synthetic pancreatic islet organoid according to claim 12, wherein the collagen support material is cross linked.

### Claim 17 (depends on 12)

The synthetic pancreatic islet organoid according to claim 12, further comprising a bioreactor containing the synthetic organoid, configured expose the synthetic organoid to an extracorporeal blood flow of a living mammal.

### Claim 18

A method of screening a drug, comprising:
providing a synthetic organoid, comprising at least one cross-linked collagen-containing surface, coated with osmotically processed acellular tissue-specific matrix extracted from a mammalian organ substantially without use of detergent, and cell growth factors comprising collagen, mucopolysaccharides, and basement membrane factors, and pluripotent stem cells cultured and induced into differentiation on the surface, to at least two organ-specific differentiated cell types;
determining a modulation of response of the synthetic organoid to glucose by a drug.

### Claim 19 (depends on 18)

The method according to claim 18, wherein the pluripotent stem cells are human pluripotent stem cells induced into four stages of differentiation into at least pancreatic beta cells; pancreatic alpha cells; pancreatic delta cells; and pancreatic polypeptide cells, and the differentiated pluripotent stem cells comprise: about 50-70% pancreatic beta cells; about 20-30% pancreatic alpha cells; about 10% pancreatic delta cells; and about <5% pancreatic polypeptide cells.

### Claim 20 (depends on 18)

The method according to claim 18, wherein the synthetic organoid is maintained within an extracorporeal blood circulation loop of a mammal.
